Continuous renal replacement therapy (CRRT) is increasingly used for the management of critically ill patients. As a consequence, the incidence of complications that accompany CRRT is also rising. However, a standardized approach for preventing or minimizing these adverse events is lacking. Dialytrauma is a newly proposed concept that encompasses all harmful adverse events related to CRRT while providing a framework for prevention or, at the least, early recognition of these events in order to attenuate the consequences. A mainstay of this approach is the utilization of a dedicated checklist for improving CRRT quality and patient safety. In this context, we discuss the most important adverse effects of CRRT and review current strategies to minimize them.

Keywords:
Dialytrauma, Renal replacement therapy, Continuous renal replacement therapy, Dialysis, Intensive care unit, Sepsis, Systemic inflammatory response syndrome, Acute kidney injury, Hemofiltration
1.
Uchino S: The epidemiology of acute renal failure in the world. Curr Opin Crit Care 2006;12:538–543.
2.
Herrera-Gutiérrez ME, Seller-Pérez G, Maynar-Moliner J, Sánchez-Izquierdo-Riera JA: Epidemiology of acute kidney failure in Spanish ICU. Multicenter prospective study FRAMI. Med Intensiva 2006;30:260–267.
3.
Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ: Acute renal failure in intensive care units: causes, outcome, and prognostic factors of hospital mortality – A prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996;24:192–198.
4.
Liaño F, Junco E, Pascual J, Madero R, Verde E: The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int 1998;66:S16–S24.
5.
Van Biesen W, Veys N, Vanholder R: Intermittent hemodialysis for renal replacement therapy in intensive care: new evidence for old truths; in Ronco C, Bellomo R, Kellum JA (eds): Acute Kidney Injury. Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 304–308.
6.
Palewsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudury D, et al, for the VA/NIH Acute Renal Trial Network: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7–20.
7.
RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627–1638.
8.
Prowle JR, Bellomo R: Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010 ;6:521–529.
9.
Maynar-Moliner J, Sánchez-Izquierdo-Riera JA, Herrera-Gutierrez M: Renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:1960–1961.
10.
Martin C, Saran R, Leavey S, Swartz R: Predicting the outcome of renal replacement therapy in severe acute renal failure. ASAIO J 2002;48:640–644.
11.
Prowle JR, Schneider A, Bellomo R: Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury John R. Critical Care 2011;15:207.
12.
Leypoldt JK, Cheung AK: Revisiting the hemodialysis dose. Semin Dial 2006;19:96–101.
13.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–1308.
14.
Druml W: ‘Dialytrauma’ – ‘Filtrationstrauma’: Wie harmlos ist die Nierenersatztherapie bei Intensivpatienten? http://www.medicom.cc/medicom-en/inhalte/intensivenews/entries/IN109/entries_sec/_Dialytrauma_Filtrationstrauma_Wie_harmlos_ist_die_Nierenersatztherapie_bei_Intensivpatienten.php.
15.
Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AHS, Herbosa T, Joseph S, Kibatala PL, Lapitan MCM, Merry AF, Moorthy K, Reznick RK, Taylor B, Gawande AA, the Safe Surgery Saves Lives Study Group: A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009;360:491–499.
16.
Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, Boer W, De Waele E, Collin V, Spapen HD: Septic AKI in ICU patients. Diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments. Ann Intensive Care 2011;9:1:32.
17.
Davenport A: Management of acute kidney injury in neurotrauma. Hemodial Int 2010;14:S27–S31.
18.
Uchino S, Bellomo R, Morimatsu H, et al: Continuous renal replacement therapy: a worldwide practice survey. The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) investigators. Intensive Care Med 2007;33:1563–1570.
19.
Santoro A, Mancini E, London G, Mercadal L, Fessy H, Perrone B, Cagnoli L, Grandi E, Severi S, Cavalcanti S: Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrol Dial Transplant 2008;23:1415–1421.
20.
Alsumrain MH, Jawad SA, Imran NB, Riar S, DeBari VA, Adelman M: Association of hypophosphatemia with failure-to-wean from mechanical ventilation. Ann Clin Lab Sci 2010;40:144–148.
21.
Troyanov S, Geadah D, Ghannoum M, Cardinal J, Leblanc M: Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy. Intensive Care Med 2004;30:1662–1616.
22.
Agarwal B, Kovari F, Saha R, Shaw S, Davenport A: Do bicarbonate-based solutions for continuous renal replacement therapy offer better control of metabolic acidosis than lactate-containing fluids? Nephron Clin Pract 2011;118:392–398.
23.
Oudemans-van Straaten HM: Primum non nocere, safety of continuous renal replacement therapy. Curr Opin Crit Care 2007;13:635–637.
24.
Frankenfield DC, Reynolds HN, Badellino MM, Wiles CE: Glucose dynamics during continuous hemodiafiltration and total parenteral nutrition. Intensive Care Med 1995;21:1016–1022.
25.
Godfrey AR: Impact of glucose levels on advanced glycation end products in hemodialysis. Hemodial Int 2007;11:278–285.
26.
Schneditz D, Zierler E, Martinelli E, Czabak-Garbacz R, Hoehlein M: Clearance, distribution volume, and dialyzer mass area transport coefficient of glucose in whole blood. ASAIO J 2012;58:137–142.
27.
Monaghan R, Watters JM, Clancey SM, Moulton SB, Rabin EZ: Uptake of glucose during continuous arteriovenous hemofiltration. Crit Care Med 1993;21:1159–1163.
28.
Bonnardeaux A, Pichette V, Ouimet D, Geadah D, Habel F, Cardinal J: Solute clearances with high dialysate flow rates and glucose absorption from the dialysate in continuous arteriovenous hemodialysis. Am J Kidney Dis 1992;19:31–38.
29.
Vaussenat F, Canaud B, Bosc JY, Leblanc M, Leray-Moragues H, Garred LJ: Intradialytic glucose infusion increases polysulphone membrane permeability and post-dilutional haemodiafiltration performances. Nephrol Dial Transplant 2000;15:511–516.
30.
Bollmann MD, Revelly JP, Tappy L, Berger MM, Schaller MD, Cayeux MC, et al: Effect of bicarbonate and lactate buffer on glucose and lactate metabolism during hemodiafiltration in patients with multiple organ failure. Intensive Care Med 2004;30:1103–1110.
31.
Javid PJ, Halwick DR, Betit P, Thompson JE, Long K, Zhang Y, et al: The first use of live continuous glucose monitoring in patients on extracorporeal life support. Diabetes Technol Ther 2005;7:431–439.
32.
Story DA, Ronco C, Bellomo R: Trace elements and vitamin concentration and losses in critically ill patients treated with continuous venovenous hemofiltration. Crit Care Med 1999;27:220–223.
33.
Cano NJ, Aparicio M, Brunori G, Carrero JJ, Cianciaruso B, Fiaccadori E, Lindholm B, Teplan V, Fouque D, Guarnieri G, ESPEN Guidelines on Parenteral Nutrition: Adult renal failure. Clin Nutr 2009;28:401–414.
34.
Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, ESPEN Guidelines on Parenteral Nutrition: Intensive care. Clin Nutr 2009;28:387–400.
35.
Berger MM, Shenkin A, Revelly JP, Roberts E, Cayeaux MC, Baines M, et al: Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients. Am J Clin Nutr 2004;80:410–416.
36.
Klein CJ, Nielsen FH, Moser-Veillon PB: Trace elements loss in urine and effluent following traumatic injury. JPEN J Parenter Enteral Nutr 2008;32:129–139.
37.
Cano N, Fiacadori E, Tesinki P, Toigo G, Druml W, Kulhmann, et al: ESPEN guidelines on enteral nutrition in adult renal failure. Clin Nutr 2006;25:295–310.
38.
Chiolero R, Berger MM: Nutritional support during renal replacement therapy. Contrib Nephrol 2007;156:267–274.
39.
Lopez Martinez J, Sanchez-Izquierdo Riera JA, Jimenez Jimenez FJ: Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus of the Spanish Society of Intensive Care Medicine and Coronary Units and the Spanish Society of Parenteral and Enteral Nutrition (SEMICYUC-SENPE): acute renal failure. Med Intensiva 2011:35(suppl):22–27.
40.
Kroh UF: Drug administration in critically ill patients with acute renal failure. New Horizons 1995;3:748–759.
41.
Maynar J: Extracorporeal clearance and extracorporeal clearance fraction: pharmacokinetic bases and drug dosing in continuous extracorporeal treatments. Nefrología 2007;27:S247–S256.
42.
Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J: A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009;64:929–937.
43.
Bergner R, Hoffmann M, Riedel KD, et al: Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019–1102.
44.
Schetz M, Ferdinande P, Van den Berghe G, et al: Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995;21:612–620.
45.
Brophy DF, Martin EJ, Gehr TW, Best AM, Paul K, Carr ME: Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006;4:372–376.
46.
Honore PM, Jacobs R, Spapen HD: Use of antifungal drugs during continuous hemofiltration therapies; in Vincent JL (ed): Annual Update in Intensive Care and Emergency Medicine. New York, Springer, 2012, pp 337–347.
47.
Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, et al, for the Hemodiafe Study Group: Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 2006;368:379–385.
48.
Arrich J, Holzer M, Herkner H, Müllner M: Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database Syst Rev 20097:CD004128.
49.
Rokyta R, Matejovic M, Krouzecky A, Opatrny, Ruzicka J, Novak I: Effects of continuous venovenous haemofiltration-induced cooling on global haemodynamics, splanchnic oxygen and energy balance in critically ill patients. Nephrol Dial Transplant 2004;19:623–630.
50.
Karakitsos D, Labropoulos N, De Groot E, Patrianakos AP, Kouraklis G, Poularas J, Samonis G, Tsoutsos DA, Konstadoulakis MM, Karabinis A: Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care 2006;10:R162.
51.
Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J, Kepros J, Goeschel C: An intervention to decrease catheter related bloodstream infections in the ICU. Engl J Med 2006;355:2725–2738.
52.
Canaud B, Desmeules S, Klouche K, Leray-Moragues H, Beraud JJ: Vascular access for dialysis in the intensive care unit. Best Pract Res Clin Anaesthesiol 2004;18:159–174.
53.
Honore PM, Joannes-Boyau O, Collin V, Boer W, Gressens B, Janvier G: Practical daily management of extra-renal continuous removal. Reanimation 2008;17:472–478.
54.
Morgan D, Ho K, Murray C, Davies H, Louw J: A randomized trial of catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. Am J Kidney Dis 2012;60:272–279.
55.
Gainza FJ, Quintanilla N, Pijoan JI, Delgado S, Urbizu JM, Lampreabe I: Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis. J Nephrol 2006;19:648–655.
56.
Lafargue M, Joannes-Boyau O, Honore PM, Gauche B, Grand H, Fleureau C, Roze H, Janvier G: Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration. ASAIO J 2008;54:124–128.
57.
Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–552.
58.
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004;50:76–80.
59.
Sakka SG, Hanusch T, Thuemer O, Wegscheider K: The influnce of venovenous renal replacement therapy on measurements by transpulmonay thermodilution technique. Anesth Analg 2007;105:1079–1082.
60.
Maynar J, Cabañes S, Fonseca F, Martín A, Castaño S, Quintano A, Saralegui I, Prieto E, Corral E, Manzano A: Termodilución transpulmonar durante tratamientos de depuración extracorpórea. ¿Son fiables los valores obtenidos? Med Intensiva 2010;34S:66–67.
61.
Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL, Program to Improve Care in Acute Renal Disease (PICARD) Study Group: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009;76:422–427.
62.
Honoré PM, Jacobs R, Joannes-Boyau O, Boer W, De Waele E, De Regt J, Spapen HD: Hemodialysis in chronic kidney disease – balancing fluid and salt on the inflammation tightrope. Int J Artif Organs 2012, E-pub ahead of print.
63.
Riegel W: Use of CRRT for detoxificacion? Int J Artif Organs 1996;9:111–112.
64.
Taccone FS, de Backer D, Laterre PF, Spapen HD, Dugernier T, Delattre I, Wallemacq P, Vincent JL, Jacobs F: Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011;37:531–535.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.